GET DAILY SIGNALSInovio Pharmaceuticals (INO) Stock Falls -24% Ahead of Key FDA Date
Key Takeaways
- Inovio Pharmaceuticals (INO) shares fell roughly 24% over the last 30 days, declining from about $1.17 to $0.89, extending a volatile stretch into late October.
- The slide reflects heightened uncertainty ahead of the U.S. FDA's October 30, 2026 target action date for INO-3107, the company's lead candidate for recurrent respiratory papillomatosis (RRP).
- A Zacks Research downgrade to Hold on October 12, 2026, and approaching lock-up expirations tied to July's equity offering weighed on near-term sentiment.
- The broader quarter was choppy: the stock plunged on July dilution, rebounded above $1.40 in early September, then trended steadily lower.
- A narrower second-quarter net loss and a cash runway into late first-quarter 2027 provide some balance against the binary regulatory risk.
- Get more detail on this ticker's Price Targets, Earnings, and Forecast.
- Explore how top-performing Trending AI Robots are positioning across the market.
Inovio Pharmaceuticals (INO) Company Overview and Market Position
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on DNA medicines designed to treat and protect against HPV-related diseases, cancer, and infectious diseases. Its platform uses proprietary investigational CELLECTRA delivery devices to administer DNA plasmids without chemical adjuvants, lipid nanoparticles, or viral vectors.
The company's lead candidate, INO-3107, is under FDA review for the treatment of recurrent respiratory papillomatosis (RRP), a rare, chronic disease caused by HPV types 6 and 11. Inovio's broader pipeline includes INO-3112 for HPV-related oropharyngeal cancer, VGX-3100 for cervical and anal high-grade lesions, and INO-5401 for glioblastoma. Investors follow the stock primarily for its binary regulatory catalyst and the potential first commercial launch from its DNA medicines platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Inovio Pharmaceuticals (INO) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INO declined from a closing price of $1.17 on September 28, 2026, to $0.89 on October 27, 2026, a drop of approximately 23.9%. The move was not linear; the stock posted sharp single-session declines in mid-October, including a slide from $1.01 to $0.80 on October 21, before stabilizing near the $0.85–$0.90 range.
The last quarter tells a broader story of extreme volatility. In late July, the stock traded around $1.03, then collapsed roughly 37% in a single session on July 30 following a public equity offering that raised about $18.3 million in net proceeds. Shares subsequently recovered on second-quarter results and analyst upgrades, climbing above $1.40 by early September, before a sustained decline brought the stock back toward $0.89. Net of the swing, INO is down roughly 14% over the trailing three months.
What Drove INO Stock Price in the Last 30 Days
The dominant driver of the recent decline is the approaching PDUFA target action date of October 30, 2026 for the INO-3107 Biologics License Application. With a binary regulatory outcome looming, risk positioning and profit-taking contributed to elevated volatility.
Several verified developments added pressure. On October 12, 2026, Zacks Research downgraded the stock to Hold. Separately, lock-up agreements tied to the July 2026 equity offering were scheduled to expire on October 28, 2026, creating a near-term overhang tied to potential share sales by insiders and holders of restricted units, warrants, and options. Notably, Piper Sandler reiterated a Buy rating with a $4.00 price target on October 21, underscoring the divided sentiment around the stock as the decision date neared. From what I see, this combination of regulatory uncertainty, the analyst downgrade, and dilution-related concerns outweighed the supportive elements and drove the 30-day decline.
What Drove INO Stock Performance Over the Last Quarter
The quarter was defined first by financing and then by sentiment swings around the regulatory timeline. The July 30 offering sharply diluted existing shareholders, sending the stock to a multi-month low. Inovio reported a second-quarter GAAP net loss of $6.01 million, a meaningful improvement from $23.52 million a year earlier, and guided that its cash position would fund operations into late first-quarter 2027, through a potential launch of INO-3107. An analyst upgrade and the company's progress through late-cycle review and pre-licensure inspections helped fuel a rebound toward $1.45 in early September.
Since that peak, the stock has given back those gains as the market de-risked ahead of the FDA decision, reflecting the event-driven nature of the investment case rather than any change in the underlying regulatory timeline.
INO Stock Forecast Drivers: What Investors Should Watch Next
The single most important catalyst is the FDA's decision on INO-3107, with a target action date of October 30, 2026. The outcome will directly shape the company's commercial trajectory, cash needs, and investor sentiment. Beyond the decision, investors should monitor any feedback on the confirmatory trial design, label negotiations, and the pace of a potential commercial launch supported by contract sales partner Syneos Health.
Additional factors include progress on VGX-3100 following positive Phase III data in China reported by partner ApolloBio, the advancement of the DPROT technology platform, and the company's cash position and potential future financing. Competitive dynamics in RRP, particularly relative to recently approved treatments, and broader small-cap biotech risk appetite will also influence the stock. These are forward-looking considerations, not predictions, and all investments carry risk. I'm watching this closely as the decision date approaches.
Exploring AI Tools for Biotech Stock Analysis
In my research process, I often review Tickeron’s Trending AI Robots to see how automated strategies are positioning around volatile names like this one. The page highlights top-performing bots across different timeframes and approaches, which can add useful context on momentum when paired with fundamental work on event-driven biotech stocks. It is one part of a broader toolkit that helps frame market signals without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
INO sees its Stochastic Oscillator climbs out of oversold territory
On October 27, 2026, the Stochastic Oscillator for INO moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 49 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where INO's RSI Oscillator exited the oversold zone, 40 of 51 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Following a +12.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
INO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INO as a result. In 65 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
INO moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for INO crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for INO entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. INO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.053) is normal, around the industry mean (2.974). P/E Ratio (-0.864) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of synthetic vaccines and immune therapies for cancers and infectious diseases
Industry Biotechnology
Advertisement